Get started
Travere Therapeutics, Inc. 2.5% 15-SEP-2025Travere Therapeutics, Inc. 2.5% 15-SEP-2025Travere Therapeutics, Inc. 2.5% 15-SEP-2025

Travere Therapeutics, Inc. 2.5% 15-SEP-2025

No trades
See on Supercharts
Overview
Analysis News

RTRX4685732 chart


Full chart

Key terms


Outstanding amount
‪68.90 M‬ USD
Face value
1,000.00 USD
Minimum denomination
1,000.00 USD
Coupon
2.50% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
3.82%
Maturity date
Sep 15, 2025
Term to maturity
8 months

About Travere Therapeutics, Inc. 2.5% 15-SEP-2025


Issuer
Travere Therapeutics, Inc.
Sector
Health Technology
Home page
travere.com
Issue date
Sep 10, 2018
FIGI
BBG00LWSMG97
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

RTRX4685732 analysis


Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.

RTRX4685732 news